Active Ingredient(s):Pertuzumab FDA Approved: * June 8, 2012 Pharm Company: *GENENTECH Category:Cancer
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.
Side effects in more than half the people taking it include diarrhea, hair loss, and loss of neutrophils; more than 10% experience loss of red blood cells, hypersensitivity or allergic reaction, infusio...
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion